Ex-Turing CEO Martin Shkreli injects himself into EpiPen debate, defends price hike

Former Turing Pharmaceutical CEO Martin Shkreli said via Twitter that insurers should cover some of the cost to make the drug more affordable, according to USA Today.

Mr. Shkreli, who refused to testify before Congress over his own decision to increase the price of life-saving toxoplasmosis treatment drug Daraprim, said he would be willing to testify on behalf of the Amsterdam based-drug maker Mylan if need be, according to the article.

Mylan executives are facing a barrage of criticism after increasing the price of a two-pack of EpiPens to a list price of roughly $600.

Mr. Shkreli said insurance companies are to blame and that they should jump at the chance to cover part of the cost since the EpiPen prevents patients from incurring even more expensive hospital visit.

Mr. Shkreli  live-tweeted his support of Mylan CEO Heather Bresch during her interview with CNBC.

More articles on supply chain:
11 drugmakers with the highest profit margins
FDA rejects Amgen's hormone imbalance treatment
Supply chain tip of the week: How to engage physicians in the decision-making process

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months